In the present study, Gplife Healthcare Private Limited’s ACT-12 and ACT-13, nutraceutical formulations developed using advanced phytochemistry, were compared for its safety and clinical efficacy along with standard of care in Hospitalized COVID 19 patients. The interpretation of the study parameters obtained is expressed as follows.

60.0% of cases from Test Group i.e. ACT-12 and ACT-13 along with standard of care showed PCR Negativity at Day 4 compared to 40% from the standard of care group.

76.66% of cases from Test Group i.e. ACT-12 and ACT-13 along with standard of care showed PCR Negativity at day 7 compared to 60% from the standard of care group.

No Patient continued to remain positive after the 10th day in the Test Group i.e. ACT-12 and ACT-13 along with standard of care, whereas in the standard care group 7 patients (23.3 %) were positive after 10 days.

Test group i.e. ACT-12 and ACT-13 along with standard of care showed substantial improvement in SpO2.

The average respiratory rate showed improvement after addition of ACT-12 and ACT-13 in standard of care and also subjects in same group were relieved of cough, shortness of breath, fever and Body ache, faster than subjects on only standard of care. It can be inferred that ACT-12 and ACT-13 contributed to improve disease-specific symptoms and overall quality of life of subject.

ACT-12 and ACT-13 demonstrated anti-inflammatory activity by lowering CRP and LDH levels thereby reducing risk of lung tissue injury & lung fibrosis.

Thrombocytopenia is associated with increased risk of severe disease and mortality in patients with COVID-19; it was found that there was improvement in Thrombocytopenia in group where ACT-12 and ACT-13 was added in standard of care which can reduce risk of hospitalization.

The IgG and IgM immunoglobulin levels were raised in subjects treated with ACT-12 and ACT-13 along with standard of care which can be related to improved antibody functionality and thereby the immunomodulatory activity offered.

In subjects treated with ACT-12 and ACT-13 along with standard of care, it was found improvement in fluctuated hematological parameters. No significant post treatment change in any of the biochemical investigations like liver function, kidney function, and lipid profiles. No fluctuation found in respiratory rate and blood pressure. This indicates safety of the ACT-12 and ACT-13 in management of COVID 19.

No mortality has been observed in the TEST group (ACT-12 and ACT-13 along with standard of care) throughout the study and hence this demonstrates safety of the treatment. No Patient was positive after the 10th day in the same group.

There is consensus that in severe COVID-19 infections, an exacerbated pulmonary and systemic inflammatory response occurs, with increased serum levels of inflammatory markers such as C-reactive protein (CRP) and lactic dehydrogenase (LDH), all of which may result in cytokine storms similar to SARS and MERS. In present clinical study there is reduction in parameters like CRP and LDH with quick recovery time which may lead to better management of the cytokine storm due to ACT-12 and ACT-13 addition in standard of care.

Around 13.3 % CORONA positive cases in group of ACT-12 and ACT-13 along with standard of care reported with diabetes and hypertension completely recovered without any other complications.